Results for Cladribine For MS Presented at CMSC
Data on use of cladribine tablets (EMD Serono, Rockland, MA) for treatment of relapsing multiple sclerosis (MS) were presented at the Consortium of Multiple Sclerosis Centers (CMSC) meeting in Nashville, TN. Cladribine is an investigational short-course oral therapy approved and marketed for use outside the US as MAVENCLAD. Results from the CLARITY trial include treated patients with no evidence of disease (NEDA) and radiologic outcomes.
John Walsh, Vice President, Neurology & Immunology (N&I), U.S. Medical Affairs for EMD Serono said, "This data is a further testament to our commitment to understanding MS in a deeper way and building a better future for the MS community."
EMD Serono also presented data from analyses of health economics and outcomes research (HEOR) data on the diagnosis and treatment of infertility and live birth rates in women with or without MS, and the prevalence of comorbidities in patients with or without MS. A mapping study comparing the availability of educational resources for MS patients across different geographical regions was also shared.
In the two-year CLARITY study, the most commonly reported adverse event in patients treated with cladribine tablets was lymphopenia. The incidence of infections was 48.3% with cladribine tablets and 42.5% with placebo, with 99.1% and 99.0% respectively rated mild-to-moderate by investigators.